Clinical-stage biotechnology company Abivax SA (Euronext Paris:ABVX) (Nasdaq:ABVX) said on Friday that it will make changes to its Phase 2 development programme for obefazimod in Crohn's Disease (CD) after feedback from the US Food and Drug Administration (FDA).
Abivax will modify the trial design taking into account FDA recommendations and conduct a dose ranging Phase 2b clinical trial.
Patient enrolment is expected to start in the third quarter of 2024.
The Phase 2b trial will be double-blind and placebo-controlled, evaluating three obefazimod doses over a 12-week induction period followed by a 40-week maintenance period.
These adjustments are based on initial Phase 2a IND submission feedback. Abivax does not expect the changes to impact the overall programme budget and projected supplemental New Drug Application (sNDA) submission timeline.
Pfizer's Hympavzi (marstacimab-hncq) receives US FDA approval for Hemophilia A or B treatment
Capricor begins BLA submission for deramiocel in Duchenne muscular dystrophy
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Biogen receives FDA Breakthrough Therapy Designation for felzartamab
Inspira Technologies develops new disposable kit for perfusion market
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices